News headlines about Epizyme (NASDAQ:EPZM) have been trending positive on Tuesday, Accern reports. Accern scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Epizyme earned a media sentiment score of 0.27 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 47.0378365670915 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

A number of research analysts have weighed in on the stock. Jefferies Group LLC assumed coverage on shares of Epizyme in a research note on Wednesday, September 20th. They issued a “buy” rating and a $23.00 target price on the stock. Oppenheimer Holdings Inc. reissued a “buy” rating and issued a $26.00 target price on shares of Epizyme in a research note on Tuesday, September 19th. Cann restated a “buy” rating and set a $26.00 price target on shares of Epizyme in a report on Tuesday, September 19th. Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Monday, October 16th. Finally, Royal Bank Of Canada restated a “buy” rating and set a $20.00 price target on shares of Epizyme in a report on Friday, September 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company’s stock. Epizyme has an average rating of “Buy” and an average price target of $22.67.

Shares of Epizyme (EPZM) opened at $12.00 on Tuesday. Epizyme has a 1-year low of $9.30 and a 1-year high of $20.45.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.02. equities analysts anticipate that Epizyme will post -2.23 earnings per share for the current year.

In related news, Director David M. Mott bought 200,000 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The stock was purchased at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the acquisition, the director now owns 6,000 shares of the company’s stock, valued at $91,500. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock in a transaction that occurred on Tuesday, October 24th. The shares were sold at an average price of $16.44, for a total transaction of $246,600.00. Following the completion of the sale, the insider now owns 23,123 shares of the company’s stock, valued at approximately $380,142.12. The disclosure for this sale can be found here. 25.20% of the stock is currently owned by company insiders.

WARNING: This article was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/28/favorable-press-coverage-somewhat-unlikely-to-impact-epizyme-epzm-stock-price.html.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Insider Buying and Selling by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Stock Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related stocks with our FREE daily email newsletter.